{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:48:32Z","timestamp":1784832512470,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human coronavirus NL63 (HCoV-NL63) mainly affects young children and immunocompromised patients, causing morbidity and mortality in a subset of patients. Since no specific treatment is available, this study aims to explore the anti-SARS-CoV-2 agents including favipiravir and remdesivir for treating HCoV-NL63 infection. We first successfully modelled the 3D structure of HCoV-NL63 RNA-dependent RNA polymerase (RdRp) based on the experimentally solved SARS-CoV-2 RdRp structure. Molecular docking indicated that favipiravir has similar binding affinities to SARS-CoV-2 and HCoV-NL63 RdRp with LibDock scores of 75 and 74, respectively. The LibDock scores of remdesivir to SARS-CoV-2 and HCoV-NL63 were 135 and 151, suggesting that remdesivir may have a higher affinity to HCoV-NL63 compared to SARS-CoV-2 RdRp. In cell culture models infected with HCoV-NL63, both favipiravir and remdesivir significantly inhibited viral replication and production of infectious viruses. Overall, remdesivir compared to favipiravir is more potent in inhibiting HCoV-NL63 in cell culture. Importantly, there is no evidence of resistance development upon long-term exposure to remdesivir. Furthermore, combining favipiravir or remdesivir with the clinically used antiviral cytokine interferon-alpha resulted in synergistic effects. These findings provided a proof-of-concept that anti-SARS-CoV-2 drugs, in particular remdesivir, have the potential to be repurposed for treating HCoV-NL63 infection.<\/jats:p>","DOI":"10.1038\/s41598-021-02972-y","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T11:06:05Z","timestamp":1638788765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models"],"prefix":"10.1038","volume":"11","author":[{"given":"Yining","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjan","family":"Rajpoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma","family":"Saqib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifa","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongren","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza S.","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuwei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"issue":"4","key":"2972_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/infdis\/jiaa321","volume":"222","author":"P Li","year":"2020","unstructured":"Li, P. et al. Estimating global epidemiology of low-pathogenic human coronaviruses in relation to the COVID-19 context. J. Infect. Dis. 222(4), 695\u2013696 (2020).","journal-title":"J. Infect. Dis."},{"issue":"8","key":"2972_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.tips.2020.05.002","volume":"41","author":"Z Ma","year":"2020","unstructured":"Ma, Z., Liu, J. & Pan, Q. Overwhelming COVID-19 clinical trials: Call for prospective meta-analyses. Trends Pharmacol. Sci. 41(8), 501\u2013503 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"2972_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/cid\/ciaa1386","volume":"73","author":"P Li","year":"2020","unstructured":"Li, P., Ikram, A., Peppelenbosch, M. P., Ma, Z. & Pan, Q. Systematically mapping clinical features of infections with classical endemic human coronaviruses. Clin. Infect. Dis. 73, 554\u2013555 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"2972_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/jmv.26362","volume":"93","author":"ABG da Veiga","year":"2020","unstructured":"da Veiga, A. B. G. et al. More than just a common cold: Endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults. J. Med. Virol. 93, 1002\u20131007 (2020).","journal-title":"J. Med. Virol."},{"issue":"4","key":"2972_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm1024","volume":"10","author":"L van der Hoek","year":"2004","unstructured":"van der Hoek, L. et al. Identification of a new human coronavirus. Nat. Med. 10(4), 368\u2013373 (2004).","journal-title":"Nat. Med."},{"issue":"22","key":"2972_CR6","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.1073\/pnas.0409465102","volume":"102","author":"H Hofmann","year":"2005","unstructured":"Hofmann, H. et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. U. S. A. 102(22), 7988\u20137993 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2972_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/1874357901004010076","volume":"4","author":"S Abdul-Rasool","year":"2010","unstructured":"Abdul-Rasool, S. & Fielding, B. C. Understanding human coronavirus HCoV-NL63. Open Virol. J. 4, 76\u201384 (2010).","journal-title":"Open Virol. J."},{"issue":"7","key":"2972_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. B Phys. 93(7), 449\u2013463 (2017).","journal-title":"Proc. Jpn. Acad. B Phys."},{"issue":"27","key":"2972_CR9","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","volume":"27","author":"M Costanzo","year":"2020","unstructured":"Costanzo, M., De Giglio, M. A. R. & Roviello, G. N. SARS-CoV-2: Recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr. Med. Chem. 27(27), 4536\u20134541 (2020).","journal-title":"Curr. Med. Chem."},{"key":"2972_CR10","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki, K. & Daikoku, T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 209, 107512 (2020).","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"2972_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","volume":"32","author":"FG Hayden","year":"2019","unstructured":"Hayden, F. G. & Shindo, N. Influenza virus polymerase inhibitors in clinical development. Curr. Opin. Infect. Dis. 32(2), 176\u2013186 (2019).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"2972_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","volume":"102","author":"S Joshi","year":"2020","unstructured":"Joshi, S. et al. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 102, 501\u2013508 (2020).","journal-title":"Int. J. Infect. Dis."},{"issue":"10","key":"2972_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue, M. L. et al. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 382(10), 929\u2013936 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2972_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3), 269\u2013271 (2020).","journal-title":"Cell Res."},{"issue":"3","key":"2972_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug. Discov. 19(3), 149\u2013150 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"19","key":"2972_CR16","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014Final report. N. Engl. J. Med. 383(19), 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"7467","key":"2972_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467), 346\u2013354 (2013).","journal-title":"Nature"},{"issue":"5","key":"2972_CR18","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1021\/ci700136x","volume":"47","author":"J Li","year":"2007","unstructured":"Li, J., Ehlers, T., Sutter, J., Varma-O\u2019Brien, S. & Kirchmair, J. CAESAR: A new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration. J. Chem. Inf. Model. 47(5), 1923\u20131932 (2007).","journal-title":"J. Chem. Inf. Model."},{"issue":"18","key":"2972_CR19","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1021\/jp973084f","volume":"102","author":"AD MacKerell","year":"1998","unstructured":"MacKerell, A. D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102(18), 3586\u20133616 (1998).","journal-title":"J. Phys. Chem. B"},{"issue":"11","key":"2972_CR20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/jcc.20065","volume":"25","author":"AD Mackerell Jr","year":"2004","unstructured":"Mackerell, A. D. Jr., Feig, M. & Brooks, C. L. 3rd. Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 25(11), 1400\u20131415 (2004).","journal-title":"J. Comput. Chem."},{"key":"2972_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-4939-7231-9_4","volume":"1654","author":"B Webb","year":"2017","unstructured":"Webb, B. & Sali, A. Protein structure modeling with MODELLER. Methods Mol. Biol. 1654, 39\u201354 (2017).","journal-title":"Methods Mol. Biol."},{"issue":"Web Server issu","key":"2972_CR22","doi-asserted-by":"publisher","first-page":"W294","DOI":"10.1093\/nar\/gks493","volume":"40","author":"J Ko","year":"2012","unstructured":"Ko, J., Park, H., Heo, L. & Seok, C. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res. 40(Web Server issue), W294\u2013297 (2012).","journal-title":"Nucleic Acids Res."},{"issue":"Web Server issu","key":"2972_CR23","doi-asserted-by":"publisher","first-page":"W510","DOI":"10.1093\/nar\/gkp322","volume":"37","author":"P Benkert","year":"2009","unstructured":"Benkert, P., Kunzli, M. & Schwede, T. QMEAN server for protein model quality estimation. Nucleic Acids Res. 37(Web Server issue), W510\u2013514 (2009).","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"2972_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.tim.2017.01.001","volume":"25","author":"W Wang","year":"2017","unstructured":"Wang, W., Xu, L., Su, J., Peppelenbosch, M. P. & Pan, Q. Transcriptional regulation of antiviral interferon-stimulated genes. Trends Microbiol. 25(7), 573\u2013584 (2017).","journal-title":"Trends Microbiol."},{"issue":"1","key":"2972_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","volume":"146","author":"S Trouillet-Assant","year":"2020","unstructured":"Trouillet-Assant, S. et al. Type I IFN immunoprofiling in COVID-19 patients. J. Allergy Clin. Immunol. 146(1), 206\u2013208.e202 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2972_CR26","doi-asserted-by":"publisher","first-page":"104054","DOI":"10.1016\/j.compbiomed.2020.104054","volume":"126","author":"S Skariyachan","year":"2020","unstructured":"Skariyachan, S. et al. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies\u2014Deciphering the scope of repurposed drugs. Comput. Biol. Med. 126, 104054 (2020).","journal-title":"Comput. Biol. Med."},{"key":"2972_CR27","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.ijbiomac.2020.09.098","volume":"163","author":"MSA Parvez","year":"2020","unstructured":"Parvez, M. S. A. et al. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach. Int. J. Biol. Macromol. 163, 1787\u20131797 (2020).","journal-title":"Int. J. Biol. Macromol."},{"issue":"13","key":"2972_CR28","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014A visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"issue":"5","key":"2972_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/1062936X.2015.1040453","volume":"26","author":"GP Cao","year":"2015","unstructured":"Cao, G. P. et al. A lazy learning-based QSAR classification study for screening potential histone deacetylase 8 (HDAC8) inhibitors. SAR QSAR Environ. Res. 26(5), 397\u2013420 (2015).","journal-title":"SAR QSAR Environ. Res."},{"issue":"1","key":"2972_CR30","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","volume":"1","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study. Lancet Microbe 1(1), e14\u2013e23 (2020).","journal-title":"Lancet Microbe"},{"issue":"396","key":"2972_CR31","doi-asserted-by":"publisher","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9(396), eaal3653 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2972_CR32","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 169, 104541 (2019).","journal-title":"Antiviral Res."},{"issue":"43","key":"2972_CR33","doi-asserted-by":"publisher","first-page":"26955","DOI":"10.1073\/pnas.2014441117","volume":"117","author":"SJF Kaptein","year":"2020","unstructured":"Kaptein, S. J. F. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl. Acad. Sci. U. S. A. 117(43), 26955\u201326965 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"2972_CR34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1186\/s13063-020-04891-1","volume":"21","author":"CR Hanna","year":"2020","unstructured":"Hanna, C. R. et al. Glasgow early treatment arm favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials 21(1), 935 (2020).","journal-title":"Trials"},{"issue":"5","key":"2972_CR35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/cts.12827","volume":"13","author":"K Irie","year":"2020","unstructured":"Irie, K. et al. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin. Transl. Sci. 13(5), 880\u2013885 (2020).","journal-title":"Clin. Transl. Sci."},{"issue":"7824","key":"2972_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson, B. N. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585(7824), 273\u2013276 (2020).","journal-title":"Nature"},{"issue":"19","key":"2972_CR37","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","volume":"383","author":"JD Goldman","year":"2020","unstructured":"Goldman, J. D. et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N. Engl. J. Med. 383(19), 1827\u20131837 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"2972_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00011-020-01342-0","volume":"69","author":"J Yuan","year":"2020","unstructured":"Yuan, J. et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm. Res. 69(6), 599\u2013606 (2020).","journal-title":"Inflamm. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02972-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T17:23:55Z","timestamp":1699896235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02972-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02972-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23465"}}